Literature DB >> 25841596

Oral contraception.

Ginger Evans1, Eliza L Sutton2.   

Abstract

Oral contraception (OC) remains a popular noninvasive, readily reversible approach for pregnancy prevention and, largely off label, for control of acne, hirsutism, dysmenorrhea, irregular menstruation, menorrhagia, and other menstrual-related symptoms. Many OC formulations exist, with generics offering lower cost and comparable efficacy. Certain medical conditions, including hypertension, migraine, breast cancer, and risk of venous thromboembolism (VTE), present contraindications. Blood pressure measurement is the only physical examination or testing needed before prescription. Although no OC is clearly superior to others, OCs containing the second-generation progestin levonorgestrel have been associated with lower VTE risk than those containing other progestins. Published by Elsevier Inc.

Entities:  

Keywords:  Ethinyl estradiol; Levonorgestrel; Medical eligibility criteria; Oral contraception; Venous thromboembolism

Mesh:

Substances:

Year:  2015        PMID: 25841596     DOI: 10.1016/j.mcna.2015.01.004

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  10 in total

1.  Association Between Long-term Oral Contraceptive Use and Risk of Crohn's Disease Complications in a Nationwide Study.

Authors:  Hamed Khalili; Fredrik Granath; Karin E Smedby; Anders Ekbom; Martin Neovius; Andrew T Chan; Ola Olen
Journal:  Gastroenterology       Date:  2016-02-23       Impact factor: 22.682

Review 2.  Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites.

Authors:  Olivia J Hall; Sabra L Klein
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

3.  The Impact of Hormonal Contraceptives on Breast Cancer Pathology.

Authors:  Jesse A Dorchak; Sifat Maria; Joseph L Guarinoni; Anette Duensing; Stella Somiari; Jane Cavanaugh; Brenda Deyarmin; Hai Hu; Joji Iida; Craig D Shriver; Paula A Witt-Enderby
Journal:  Horm Cancer       Date:  2018-04-23       Impact factor: 3.869

4.  Progesterone-Based Contraceptives Reduce Adaptive Immune Responses and Protection against Sequential Influenza A Virus Infections.

Authors:  Olivia J Hall; Raffael Nachbagauer; Meghan S Vermillion; Ashley L Fink; Vanessa Phuong; Florian Krammer; Sabra L Klein
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 5.  Risk of Inflammatory Bowel Disease with Oral Contraceptives and Menopausal Hormone Therapy: Current Evidence and Future Directions.

Authors:  Hamed Khalili
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

6.  Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.

Authors:  Merete Ellingjord-Dale; Linda Vos; Steinar Tretli; Solveig Hofvind; Isabel Dos-Santos-Silva; Giske Ursin
Journal:  Breast Cancer Res       Date:  2017-01-23       Impact factor: 6.466

7.  Combined Intranasal Insulin/Saxagliptin/Metformin Therapies Ameliorate the Effect of Combined Oral Contraceptive- (COC-) Induced Metabolic Syndrome (MetS) with a Major Target on Glucose Metabolism in Adult Female Wistar Rats.

Authors:  Saheed Olanrewaju Afolabi; Joy Folahan; Olalekan Agede; Olufunke Olorundare
Journal:  Int J Reprod Med       Date:  2021-12-13

8.  Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study.

Authors:  Paula Briggs; Marco Serrani; Kai Vogtländer; Susanne Parke
Journal:  Int J Womens Health       Date:  2016-09-15

9.  Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe.

Authors:  Tomas Fait; Dmitry Buryak; Monica-Mihaela Cirstoiu; Eva Luczai; Rafal Janczura
Journal:  Drugs Context       Date:  2018-02-07

10.  Occurrence of selected endocrine disrupting compounds in the eastern cape province of South Africa.

Authors:  Adebayo I Farounbi; Nosiphiwe P Ngqwala
Journal:  Environ Sci Pollut Res Int       Date:  2020-03-09       Impact factor: 4.223

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.